Inhibition of hemangioma growth using polymer-lipid hybrid nanoparticles for delivery of rapamycin.

Abstract

Although infantile hemangiomas is benign, its rapid growth may induce serious complications. However, only one drug Hemangeol™ has been approved by US Food and Drug Administration (FDA) to treat infantile hemangiomas. Thus it is necessary to develop novel alternative drugs to treat infantile hemangiomas. Rapamycin is a well-know potent antiangiogenic agent… (More)
DOI: 10.1016/j.biopha.2017.08.035

Topics

Cite this paper

@article{Li2017InhibitionOH, title={Inhibition of hemangioma growth using polymer-lipid hybrid nanoparticles for delivery of rapamycin.}, author={Haitao Li and Yunfei Teng and Jin Sun and Jianyong Liu}, journal={Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie}, year={2017}, volume={95}, pages={875-884} }